VDRM
ViaDerma, Inc.
A Division of ViaDerma, Inc. , A Public Company.
Breakthrough Rapid Delivery of Nutrients and Medicines
ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.
About Our Products
Proprietary and Trade Secret Mechanism of Action
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
Skin Layer Organization
A second important result of RAIDS is that the topical antibiotic [b]kills all harmful Gram positive and Gram negative bacteria that have been available for testing.[/b] We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
APPLICATIONS & USAGE
We are developing products in the following fields of use;
Topical antibiotics
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal
Acne
Psoriasis
Eczema
Topical toenail antifungal
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Anti-viral formula
Treats symptoms of Influenza which is a$4B/ year global market: Common
Estimated Global prevalence rate of Influenza: 355-1065 million.
Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care
Diabetic foot wounds.
Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year
Contact Details
ViaDerma's global headquarters is located at
8950 W. Olympic Blvd, Suite 576, Beverly Hills, CA 90211.
We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.
Phone: 310.871.3996
Headlines Get Headlines for:
Tuesday, August 5, 2014
ViaDerma, Inc. Announces Strategic Partnership With The Brewer GroupPR Newswire (Tue, Aug 5)
Tuesday, June 10, 2014
VIADERMA INC FinancialsEDGAR Online Financials (Tue, Jun 10)
Older Headlines - Most Recent Headlines
--------------------------------------------------------------------------------